142 related articles for article (PubMed ID: 21221804)
1. U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.
Ho SB; Aqel B; Dieperink E; Liu S; Tetrick L; Falck-Ytter Y; DeComarmond C; Smith CI; McKee DP; Boyd W; Kulig CC; Bini EJ; Pedrosa MC
Dig Dis Sci; 2011 Mar; 56(3):880-8. PubMed ID: 21221804
[TBL] [Abstract][Full Text] [Related]
2. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
Yee HS; Currie SL; Tortorice K; Cozen M; Shen H; Chapman S; Cunningham F; Monto A
Dig Dis Sci; 2011 Aug; 56(8):2439-48. PubMed ID: 21633833
[TBL] [Abstract][Full Text] [Related]
3. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
Malone DC; Tran TT; Poordad FF
J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
[TBL] [Abstract][Full Text] [Related]
4. The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients.
Pockros PJ; Reindollar R; McHutchinson J; Reddy R; Wright T; Boyd DG; Wilkes LB
J Viral Hepat; 2003 Jan; 10(1):55-60. PubMed ID: 12558913
[TBL] [Abstract][Full Text] [Related]
5. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
[TBL] [Abstract][Full Text] [Related]
6. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
Zeuzem S; Berg T; Gane E; Ferenci P; Foster GR; Fried MW; Hezode C; Hirschfield GM; Jacobson I; Nikitin I; Pockros PJ; Poordad F; Scott J; Lenz O; Peeters M; Sekar V; De Smedt G; Sinha R; Beumont-Mauviel M
Gastroenterology; 2014 Feb; 146(2):430-41.e6. PubMed ID: 24184810
[TBL] [Abstract][Full Text] [Related]
7. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.
Satapathy SK; Lingisetty CS; Proper S; Chaudhari S; Williams S
J Clin Gastroenterol; 2010 Feb; 44(2):140-5. PubMed ID: 19826275
[TBL] [Abstract][Full Text] [Related]
8. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
[TBL] [Abstract][Full Text] [Related]
9. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319
[TBL] [Abstract][Full Text] [Related]
11. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
[TBL] [Abstract][Full Text] [Related]
13. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
14. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
15. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.
Layden TJ; Layden JE; Reddy KR; Levy-Drummer RS; Poulakos J; Neumann AU
J Viral Hepat; 2002 Sep; 9(5):334-9. PubMed ID: 12225327
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.
Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Rajender Reddy K
J Hepatol; 2012 May; 56(5):1012-1018. PubMed ID: 22266603
[TBL] [Abstract][Full Text] [Related]
17. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6.
Lam KD; Trinh HN; Do ST; Nguyen TT; Garcia RT; Nguyen T; Phan QQ; Nguyen HA; Nguyen KK; Nguyen LH; Nguyen MH
Hepatology; 2010 Nov; 52(5):1573-80. PubMed ID: 21038410
[TBL] [Abstract][Full Text] [Related]
19. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
